Evidence map›Paper›PMID 22302271›Full record

ArticleAnnals of surgical oncology2012

Chronic anti-inflammatory drug therapy inhibits gel-forming mucin production in a murine xenograft model of human pseudomyxoma peritonei.

Haroon Asif Choudry, Arun Mavanur, Mark E O'Malley, Herbert J Zeh, Z Sheng Guo, David L Bartlett

Abstract read
In one paragraph

Article in Annals of surgical oncology, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
3.8field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 30 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Review
  5. Review
  6. Article
  7. Article
  8. Article
  9. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

Haroon Asif ChoudryDivision of Surgical Oncology, University of Pittsburgh Medical Center, Pittsburgh, PA, USA. choudrymh@upmc.edu
Arun Mavanur
Mark E O'Malley
Herbert J Zeh
Z Sheng Guo
David L Bartlett
University of Pittsburgh Medical Center · US

Funding

Postdoctoral Research Training in Biotherapy of CancerT32CA113263 · NCI · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI Udai S Kammula · 2006 to 2026
$3.6M
NCI NIH HHS T32 CA113263
6 · The paper itself

Abstract

backgroundIntraperitoneal accumulation of mucinous ascites in pseudomyxoma peritonei (PMP) promotes an inflammatory/fibrotic reaction that progresses to bowel obstruction and eventual patient demise. Cytokines and inflammation-associated transcription factor binding sites, such as glucocorticoid response elements and COX-2, regulate secretory mucin, specifically MUC2, production. We hypothesized that anti-inflammatory drugs targeting inflammation-associated pathways may reduce mucin production and subsequent disease morbidity in PMP.

methodsThe effects of dexamethasone and Celebrex were assessed in mucin-secreting human colon cancer LS174T cells in vitro and murine xenograft models of LS174T and human appendiceal PMP in vivo by serial parametric measurements, MUC2 transcripts via real-time RT-PCR, and MUC2 protein expression via immunofluorescence assays.

resultsDexamethasone significantly inhibited basal MUC2 mRNA levels in LS174T cells, inhibited mucinous tumor accumulation in an intraperitoneal PMP xenograft model, and prolonged survival in a subcutaneous LS174T xenograft model. Celebrex significantly inhibited sodium butyrate-stimulated MUC2 mRNA levels in LS174T cells and demonstrated a statistically nonsignificant trend toward reduced mucinous tumor growth and prolonged survival in the xenograft models. MUC2 protein analysis by immunofluorescence demonstrated a dual effect of dexamethasone on mucin production and tumor cell count.

conclusionsInflammatory mediators are known to regulate mucin production and may promote overexpression of MUC2 by neoplastic cells with goblet cell phenotype in PMP. Anti-inflammatory drugs, dexamethasone and Celebrex, could inhibit extracellular mucin production in PMP by targeting inflammatory cascades and, therefore, may decrease compressive symptoms, increase the disease-free interval, and reduce the extent or frequency of morbid cytoreductive surgeries.

Indexed as

Administration, OralAnimalsAnti-Inflammatory AgentsAppendiceal NeoplasmsCelecoxibColonic NeoplasmsDexamethasoneDisease Models, AnimalDose-Response Relationship, DrugDrug Administration ScheduleHumansMiceMice, NudeMucin-2Neoplasm Recurrence, LocalPeritoneal NeoplasmsAnti-Inflammatory AgentsCelecoxibDexamethasoneMUC2 protein, humanMucin-2PyrazolesSulfonamides

Identifiers

PMID22302271
PMCPMC4125010
OpenAlexW2038584900

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.